2. Academic Validation
  3. A new class of anticancer activity with computational studies for a novel bioactive aminophosphonates based on pyrazole moiety

A new class of anticancer activity with computational studies for a novel bioactive aminophosphonates based on pyrazole moiety

  • Sci Rep. 2023 Sep 6;13(1):14680. doi: 10.1038/s41598-023-40265-8.
Mohamed H Baren 1,  Seham A Ibrahim 2,  Munirah M Al-Rooqi 3,  Saleh A Ahmed 4,  Mohammed M El-Gamil 5,  Hend A Hekal 1
Affiliations

Affiliations

  • 1 Chemistry Department, Faculty of Science, Tanta University, Tanta, 31527, Egypt.
  • 2 Chemistry Department, Faculty of Science, Tanta University, Tanta, 31527, Egypt. [email protected].
  • 3 Department of Chemistry, Faculty of Applied Sciences, Umm Al-Qura University, Makkah, 21955, Saudi Arabia.
  • 4 Department of Chemistry, Faculty of Applied Sciences, Umm Al-Qura University, Makkah, 21955, Saudi Arabia. [email protected].
  • 5 Department of Toxic and Narcotic Drug, Forensic Medicine, Mansoura Laboratory, Medico legal Organization, Ministry of Justice, Mansoura, Egypt.
PMID: 37673913 DOI: 10.1038/s41598-023-40265-8
Abstract

The present study involves synthesis a new series of α-aminophosphonates 2a-f and 4a-d derivatives in good yield with a simple workup via Kabachnik-Fields reaction in the presence of lithium perchlorate as Lewis acid catalyst. All the newly synthesized compounds were confirmed using various physical, spectroscopic, and analytical data. The in vitro Anticancer activities of each compound were evaluated against colorectal carcinoma Colon Cancer (HCT-116) and Epdermoid carcinoma (HEP2) and also Human lung fibroblast normal cell line (WI38) compared with Doxorubicin. The results showed that Compounds 2a, 4b and 4d exhibited more potent inhibitory activity for Epdermoid Carcinoma (HEP2) compared with doxorubicin. For colon carcinoma cells (HCT-116) Compounds 2a, 2d and 4b gave the strongest activity among all compounds compared with doxorubicin. Moreover, all designed structures were docked into the active site of VEGFR2/KDR/Flk-1 and FGFR1 proteins. The result reveals that compound 2b and have the strongest inhibitory activity of the VEGFR2/KDR/Flk-1 and FGFR1 proteins indicating that these substances might conceivably operate as VEGFR2/KDR/Flk-1 and FGFR1 inhibitors and hence might take role in Anticancer activities with various binding interactions. The 3D-QSAR models produced strong statistical results since they were defined by PLS factors 4 and confirmed by parameters as R2, R2 CV, Stability, F-value, P-value, RMSE, Q2, and Pearson-r.

Figures
Products